Compare BOE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOE | DRUG |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.4M | 707.1M |
| IPO Year | N/A | 2020 |
| Metric | BOE | DRUG |
|---|---|---|
| Price | $11.81 | $67.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | 110.0K | ★ 332.7K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.59 | $23.18 |
| 52 Week High | $12.18 | $123.75 |
| Indicator | BOE | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 36.41 |
| Support Level | $11.75 | $49.47 |
| Resistance Level | $11.79 | $70.23 |
| Average True Range (ATR) | 0.15 | 5.31 |
| MACD | -0.04 | -1.77 |
| Stochastic Oscillator | 35.29 | 25.27 |
Blackrock Enhanced Global Dividend Trust is a closed-end management investment company. Its investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in equity securities issued by companies located in countries throughout the world.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.